Cardiac amyloidosis continues to get more and more attention at cardiology meetings. At Heart Failure 2026 in Spain, it was the topic of multiple studies, including one on the benefits of acoramidis.
Up to 30% of U.S. patients carry genetic variations that reduce the effectiveness of clopidogrel, an antiplatelet medication sold under the brand name Plavix.
This new catheter-based device for lymphatic drainage showed early potential to be an effective treatment option for acute decompensated heart failure.
The REVEAL study has been assessing the sensitivity and specificity of iodine 124 evuzamitide (I 124 evuzamitide), a PET agent capable of visualizing signs of cardiac amyloidosis on imaging.
Although DBT exams are proven to identify more difficult to detect cancers, especially among women with dense breasts, they also include significantly more images than standard 2D mammograms.
Devi Nair, MD, director of cardiac electrophysiology with St. Bernard's Heart and Vascular Center, discussed her experience using a new-look Medtronic pulsed field ablation (PFA) system to treat persistent AFib.
A Cleveland Clinic researcher accepted NIH funding without telling the agency about money coming in for the same project from one or more foreign backers. For this the nonprofit Cleveland Clinic Foundation will pay $7.6 million.
Up to 30% of patients have metastatic disease by the time they are initially diagnosed with renal cell carcinoma, making accurate staging a critical element of treatment planning.
Experts have identified numerous white matter features, in addition to changes in white matter tracts that occur over time, which they believe are more common among people with ADHD.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/top_stories/public/2024-09/istock-1209664264.jpg.webp?itok=gQInU1vO)
